glp-1 sglt2 combination Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM) | Cardiovascular Diabetology Safety, efficacy, and cardiovascular benefits

Novel Treatments in Lung Cancer

Direct and indirect anti-fibrotic mechanisms of incretin agonists across organ systems

Analysts project that while Novo and Lilly will likely retain nearly 70% of the total market through 2031 due to first-mover advantages and continued pipeline innovation, new entrants could collectively capture approximately $70 billion of what is expected to become a $200 billion annual market [46]

Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, and Bloom SR

Others are adding wellness programs emphasizing nutrition and exercise, sometimes contingent on GLP-1 use